He is the Director of Transplantation for the Hunter New England LHD, a transplant physician and nephrologist. His research commitments are antibody mediated rejection; immunosuppression in renal transplantation; ischaemia reperfusion injury and tolerance in transplantation. He led the research that found an integrin molecule αvβ6 was expressed in the epithelium of the kidney when it was rejected or injured by ischaemia. He pioneered the application of desensitization of recipients before live donor transplantation and started ABO incompatible renal transplantation here. With colleagues he is evaluating a technique for the early detection of glomerular rejection. He is member of the scientific advisory committee of the Hunter Transplant Research Foundation.
He is a transplant immunologist and transplant surgeon. He was the Foundation Director of Transplantation for the HNELHD from 1985 to 2010. His research commitments are the evaluation of a novel immunosuppressive molecule, Castanospermine; the epidemiology of cancer in transplantation; ischaemia reperfusion injury and tolerance. He led the research that found a transplant immunosuppressive molecule, Castanospermine, which works by impairing the binding of cells to vascular endothelium. With colleagues he found that pretransplant immunosuppressive drugs conferred increased risks of virally related cancers in transplantation. He led the research that set up an instrument for measuring potential deceased donation now adopted in Australia. He also found that tolerance to an organ transplant could be achieved by high doses of donor derived class 1 antigen borne on platelets. He is member of the scientific advisory committee of the Hunter Transplant Research Foundation.
He is a transplant physician in the HNELHD and researcher with commitments to the prevention of infection in transplantation. He has published on the role of leflunomide in the management of cytomegalovirus infection.
He is the technical officer in the Newcastle Transplant Unit and manages the transplant immunology laboratory. He has particular expertise in flow cytometry and microsurgery. He has played a pivotal role in working out the immunosuppressive effect and mechanism of action of Castanospermine, a novel immunosuppressant in transplantation.
He is a staff transplant surgeon and researcher within the HNELHD. His research commitments are the detection and significance of transplant artery stenosis, laparoscopic donor nephrectomy and development of business intelligence software for Transnet. He has devised a method to detect and prevent renal transplant compression syndrome.
He is a transplant surgeon and urologist. He is Head of Transplant Surgery with the HNELHN. He introduced laparoscopic donor nephrectomy here. His research commitments are the use of kidneys, restored after cancer excision, for transplantation and laparoscopic donor nephrectomy. He has found that the transplantation of kidneys after excision of a primary renal cancer can be done successfully in senior recipients.
She is a transplant physician and nephrologist. Her research commitments are immunological tolerance and immunosuppression in renal transplantation. She has found an association between recipient non responsiveness and the loss of complement fixation in donor specific antibodies.
She is a transplant physician and nephrologist. Her research commitments are glomerular rejection and immunosuppression in renal transplantation. She has found that deposition of a complement derivative in the glomerulus of a transplanted kidney is associated with poor transplant prognosis and is likely to be a form of antibody mediated rejection.